J Korean Diabetes.  2018 Mar;19(1):35-40. 10.4093/jkd.2018.19.1.35.

Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association

• Kim HJ

• KMID: 2408656
• DOI: http://doi.org/10.4093/jkd.2018.19.1.35

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy, which was a change from the previous guideline that recommended them only as a combination therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) have demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RAs may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.

Keyword

Cardiovascular diseases; Diabetes mellitus; Glucagon-like peptide-1 receptor agonist; Hypoglycemia; Obesity; Practice guideline

MeSH Terms

Cardiovascular Diseases
Diabetes Mellitus
Diabetes Mellitus, Type 2*
Glucagon-Like Peptide 1*
Glucagon-Like Peptide-1 Receptor*
Humans
Hypoglycemia
Hypoglycemic Agents
Insulin
Obesity
Weight Loss
Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Insulin